PVCT
PROVECTUS BIOPHARMACEUTICALS, INC.
Next earnings Aug 12, 2026
$0.07
▲ +2.99%$0.07▼ -8.00%
over 1Y
L $0.04H $0.10
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+3.0%
1W+0.0%
1M+11.3%
3M+43.8%
YTD+7.8%
1Y-8.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
High return on equity (86.2%); but revenue fell -45.5% YoY.
Revenue (FY2025) $336K · FY2025
PROVECTUS BIOPHARMACEUTICALS, INC. shows $336K in FY2025 revenue (-45.5% YoY), a -1615.8% net margin, and 86.2% ROE.
Supporting the case: high return on equity (86.2%); conservative balance sheet (liabilities/equity -1.11x).
Is PVCT a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread (caution)~60d expiry
- Long put 0 @ ~0.00 est
- Short put 0 @ ~0.00 est
debit $0max +$0max $0
AVOID means we wouldn't engage at all — if expressing the short side anyway, only with capped risk.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | $989K | $558K | $617K | $336K |
| Gross profit | — | — | — | — | — |
| Operating income | -$4.67M | -$3.43M | -$2.90M | -$4.53M | -$5.29M |
| Net income | -$5.54M | -$3.55M | -$3.10M | -$4.73M | -$5.43M |
| Diluted EPS | — | -$0.01 | -$0.01 | -$0.01 | -$0.01 |
| Net margin | — | -359.4% | -556.2% | -766.9% | -1615.8% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$29.2M
EV / EBITDA—
EV / Sales87.0
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-18.7%
FCF yield-11.6%
Quality & risk
ROIC (est.)—
Free cash flow-$3.36M
Total debt$500K
Net cash-$249K
Altman Z-Score-560.56 distress
Piotroski F-Score2/7
Capital returns
Buyback yield0.0%
Dividend yield (est.)—
Shareholder yield0.0%
Shares Δ YoY+0.0%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-302026-07-02open ↗8-KPeriod ending 2026-06-302026-07-01open ↗4Period ending 2026-06-302026-06-30open ↗4Period ending 2026-06-302026-06-30open ↗4Period ending 2026-06-302026-06-30open ↗8-KPeriod ending 2026-06-182026-06-22open ↗8-KPeriod ending 2026-06-182026-06-18open ↗4Period ending 2026-06-052026-06-05open ↗4Period ending 2026-05-282026-05-29open ↗4Period ending 2026-05-232026-05-26open ↗4Period ending 2026-05-152026-05-15open ↗10-QPeriod ending 2026-03-312026-05-14open ↗
Frequently asked
- Is PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT) a buy?
- PVCT currently carries a Avoid rating with 3/5 conviction, derived from its latest SEC filings. High return on equity (86.2%); but revenue fell -45.5% YoY.
- What is PROVECTUS BIOPHARMACEUTICALS, INC.'s quality score?
- PVCT scores 25.258287509819326/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0000315545, latest 10-Q filed 2026-05-14) · EODHD · as of 6/18/2026, 1:07:44 PM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 18, 2026, 9:07 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.